ACTON, Mass.– Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand, announced today that Flavia Pease will be appointed Executive Vice President and Chief Financial Officer effective September 30, 2025. She will succeed Ana Maria Chadwick, who will transition into a Senior Advisor role to support a smooth handover.
“I want to personally thank Ana, who has provided steady and thoughtful leadership for Insulet during a period of significant growth,” said Ashley McEvoy, President and Chief Executive Officer of Insulet. “She has been instrumental in strengthening our financial foundation and positioning us for continued success.”
Chadwick added, “It has been a privilege to help advance Insulet’s mission. I am confident in the team and the Company’s continued momentum.”
Pease brings more than two decades of global healthcare and medical technology industry experience. Most recently, she served as Corporate Executive Vice President and Chief Financial Officer at Charles River Laboratories. Before that, she spent over 20 years at Johnson & Johnson, including roles as Vice President and Group Chief Financial Officer of its global Medical Devices business, a $27 billion portfolio, and Vice President of Finance for Janssen North America, the company’s largest business unit.
Since January 2024, Pease has served on Insulet’s Board of Directors and Audit Committee, giving her deep familiarity with the company’s strategy and operations. She will resign from the Board as she assumes her new executive role.
“Flavia is a highly accomplished business leader with world-class healthcare and MedTech expertise,” said McEvoy. “Her proven ability to drive financial performance, lead global operations, and create value makes her the ideal CFO to guide Insulet’s next phase of patient-centric growth. Her contributions as a Board member have already been instrumental to our strong performance, and we expect a seamless transition.”
Pease said she is eager to take on the new position: “I am thrilled to join this talented leadership team as CFO and to continue serving this outstanding Company. Insulet’s commitment to improving the lives of people with diabetes is deeply inspiring, and I look forward to working with Ashley, the Board, and the team to build on Insulet’s strong foundation, accelerate growth, and deliver lasting value for customers and shareholders.”
